Real-World Comparison of Cardiovascular Benefits Between Sodium-Glucose Cotransporter 2 Inhibitors (SGLT-2i) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D)

Type 2 Diabetes is a chronic condition that affects millions of people worldwide and is associated with an increased risk of cardiovascular complications, including congestive heart failure, stroke, and peripheral artery disease. This research examined which of two classes of medications commonly prescribed for the management of Type 2 diabetes—SGLT-2i, sodium-glucose cotransporter-2 inhibitors or GLP-1RA, glucagon-like peptide-1 receptor agonists— had more cardiovascular benefits for patients.

The real-world data suggests that SGLT-2i may offer greater cardioprotective benefits beyond just glycemic control versus GLP-1RA users. These findings may be useful for clinical decision-making but should also be weighed against the potential risk of adverse events associated with SGLT-2i.

This poster was featured during Poster Session 5 on Wednesday, May 10, 2023, at the International Society for Pharmacoeconomics and Outcomes (ISPOR) 2023 Conference.

Download the poster here